Emily E. Morin

1.4k total citations · 1 hit paper
21 papers, 1.0k citations indexed

About

Emily E. Morin is a scholar working on Surgery, Cancer Research and Molecular Biology. According to data from OpenAlex, Emily E. Morin has authored 21 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 6 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Emily E. Morin's work include Cholesterol and Lipid Metabolism (7 papers), Lipoproteins and Cardiovascular Health (5 papers) and Cancer, Lipids, and Metabolism (4 papers). Emily E. Morin is often cited by papers focused on Cholesterol and Lipid Metabolism (7 papers), Lipoproteins and Cardiovascular Health (5 papers) and Cancer, Lipids, and Metabolism (4 papers). Emily E. Morin collaborates with scholars based in United States, China and Russia. Emily E. Morin's co-authors include Anna Schwendeman, Hongliang He, Min Liu, Lisha Liu, Minzhi Yu, Ling Guo, Wenmin Yuan, Ekaterina I. Shishatskaya, Steven P. Schwendeman and Yanhong Guo and has published in prestigious journals such as Accounts of Chemical Research, Advanced Drug Delivery Reviews and The FASEB Journal.

In The Last Decade

Emily E. Morin

20 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures

2019 425 citations Hongliang He, Lisha Liu et al. Accounts of Chemical Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emily E. Morin United States	12	394	302	286	226	174	21	1.0k
Leyuan Xu United States	26	615 1.6×	181 0.6×	159 0.6×	357 1.6×	152 0.9×	36	1.4k
Minzhi Yu United States	17	632 1.6×	398 1.3×	325 1.1×	117 0.5×	248 1.4×	38	1.3k
Yawen Guo China	18	326 0.8×	95 0.3×	142 0.5×	133 0.6×	122 0.7×	51	1.0k
Rose Ackermann United States	19	318 0.8×	226 0.7×	98 0.3×	209 0.9×	93 0.5×	29	983
Ian R. Corbin United States	23	685 1.7×	386 1.3×	379 1.3×	226 1.0×	112 0.6×	54	1.8k
Juan Cheng China	19	342 0.9×	104 0.3×	170 0.6×	132 0.6×	366 2.1×	48	1.3k
Mark E. Lobatto Netherlands	16	444 1.1×	531 1.8×	501 1.8×	340 1.5×	387 2.2×	24	1.6k
Jeong Uk Choi South Korea	20	383 1.0×	259 0.9×	220 0.8×	95 0.4×	109 0.6×	57	967
Enayat Anvari Iran	17	358 0.9×	228 0.8×	221 0.8×	58 0.3×	251 1.4×	39	1.1k
Sijia He China	13	522 1.3×	92 0.3×	290 1.0×	55 0.2×	135 0.8×	30	1.1k

Countries citing papers authored by Emily E. Morin

Since Specialization

Citations

This map shows the geographic impact of Emily E. Morin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily E. Morin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily E. Morin more than expected).

Fields of papers citing papers by Emily E. Morin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily E. Morin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily E. Morin. The network helps show where Emily E. Morin may publish in the future.

Co-authorship network of co-authors of Emily E. Morin

This figure shows the co-authorship network connecting the top 25 collaborators of Emily E. Morin. A scholar is included among the top collaborators of Emily E. Morin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily E. Morin. Emily E. Morin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morin, Emily E., et al.. (2023). Single-cell transcriptomic heterogeneity between conduit and resistance mesenteric arteries in rats. Physiological Genomics. 55(4). 179–193. 3 indexed citations

Kim, Sang Yeop, Maria V. Fawaz, Minzhi Yu, et al.. (2023). Phospholipids Impact the Protective Effects of HDL-Mimetic Nanodiscs Against Lipopolysaccharide-Induced Inflammation. Nanomedicine. 18(29). 2127–2142. 2 indexed citations

Yuan, Wenmin, Rui Kuai, Emily E. Morin, et al.. (2022). Systematic evaluation of the effect of different apolipoprotein A-I mimetic peptides on the performance of synthetic high-density lipoproteins in vitro and in vivo. Nanomedicine Nanotechnology Biology and Medicine. 48. 102646–102646. 10 indexed citations

Guo, Ling, Emily E. Morin, Minzhi Yu, et al.. (2022). Replenishing HDL with synthetic HDL has multiple protective effects against sepsis in mice. Science Signaling. 15(725). eabl9322–eabl9322. 29 indexed citations

Morin, Emily E., et al.. (2022). EC Membrane Cholesterol Content Regulates the Contribution of TRPV4 Channels in ACh‐induced vasodilation in Rat Gracilis Arteries. The FASEB Journal. 36(S1). 1 indexed citations

Morin, Emily E., et al.. (2022). Role of Cholesterol in the Regulation of Hydrogen Sulfide Signaling within the Vascular Endothelium. Antioxidants. 11(9). 1680–1680. 3 indexed citations

Morin, Emily E., Yanhong Guo, Hongliang He, et al.. (2020). Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice. Frontiers in Pharmacology. 11. 513031–513031. 11 indexed citations

Yuan, Wenmin, Bilian Yu, Minzhi Yu, et al.. (2020). Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport. Journal of Controlled Release. 329. 361–371. 33 indexed citations

Schultz, Mark L., Maria V. Fawaz, Todd Hollon, et al.. (2019). Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases. BMC Medicine. 17(1). 200–200. 18 indexed citations

10.

He, Hongliang, Lisha Liu, Emily E. Morin, Min Liu, & Anna Schwendeman. (2019). Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures. Accounts of Chemical Research. 52(9). 2445–2461. 425 indexed citations breakdown →

11.

Kim, Sang Yeop, et al.. (2019). High‐Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis & Rheumatology. 72(1). 20–30. 59 indexed citations

12.

Yu, Minzhi, et al.. (2018). Battle of GLP-1 delivery technologies. Advanced Drug Delivery Reviews. 130. 113–130. 116 indexed citations

13.

Morin, Emily E., Xiang‐An Li, & Anna Schwendeman. (2018). HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. Frontiers in Endocrinology. 9. 715–715. 25 indexed citations

14.

Li, Dan, Maria V. Fawaz, Emily E. Morin, et al.. (2017). Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics. Molecular Pharmaceutics. 15(1). 83–96. 20 indexed citations

15.

Guo, Yanhong, Wenmin Yuan, Bilian Yu, et al.. (2017). Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression. EBioMedicine. 28. 225–233. 77 indexed citations

16.

Tang, Jie, Dan Li, Lindsey Drake, et al.. (2016). Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization. Journal of Lipid Research. 58(1). 124–136. 27 indexed citations

17.

Taylor, Matthew, et al.. (2016). Synthetic High-Density Lipoprotein (sHDL) Inhibits Steroid Production in HAC15 Adrenal Cells. Endocrinology. 157(8). 3122–3129. 5 indexed citations

18.

Morin, Emily E., et al.. (2015). HDL in sepsis – risk factor and therapeutic approach. Frontiers in Pharmacology. 6. 244–244. 96 indexed citations

19.

Schwendeman, Anna, Denis Sviridov, Wenmin Yuan, et al.. (2015). The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties. Journal of Lipid Research. 56(9). 1727–1737. 79 indexed citations

20.

Morin, Emily E.. (2015). The Late Works of Dame Ethel Smyth: A Musical Microcosm of Interwar British Culture.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact